Alembic to launch new drug delivery system
By Praveen Chandran | 05 Aug 2002
Mumbai: The domestic pharma company Alembic Ltd will shortly launch a novel drug delivery system for nimesulide namely Nimegesic OD. This NDDS for nimesulide has been developed for the first time at the Alembic Research Centre.
Nimegesic OD is designed using 'synergistic technology' and is a bilayered tablet from which the active drug is released in two stages. Immediate relief is offered by instant release of the drug in the first stage, and the subsequent release ensures a prolonged effect.
Alembic vice-president (formulations) Atul Barman says: “Recent trends of mergers and acquisitions and IPR compliance in the Indian pharma industry will have significant impact on the way we do business, and the emerging area of NDDS design is a stepping stone to exciting business opportunities.“
Alembic's Nimegesic OD will soon offer patients for the first time, the convenience of a once-daily dosage for effective pain management therapy for chronic ailments. Nimesulide is a widely used non-steroidal, anti-inflammatory drug and is indicated for pain, fever, and inflammation. This is a sequel to Alembic's Nimegesic IR launched in January 2000.
Nimegesic OD will hit the market the market by mid-August 2002, and is expected to contribute Rs 3 crore in the first year of launch, thus bolstering the company's growth plans.